Whole-exome and whole-genome sequencing studies have revealed a high number of somatic copy number alterations and mutations in pancreatic cancer, leading to altered expression of key oncogenes and tumor suppressor genes, such as KRAS, TP53, SMAD4, and CDKN2A [23,24,25,26]. This evidence concerns the gene TP53 and familial pancreatic carcinoma.